SITC 2026 at a glance
SITC 2026 will spotlight emerging cancer immunotherapies, including bispecific antibodies, cancer vaccines, in vivo cell engineering and engineered cytokines. Advances in AI-driven therapeutic design and response prediction will also feature, alongside clinical and industry developments that could shape the future of immuno-oncology.
Which emerging immuno-oncology platforms can turn scientific promise into clinical and competitive advantage?
📅 Build your schedule around the sessions that matter most.
📥 Download the SITC_2026_Preview_by_LucidQuest
Key Immuno-Oncology Themes at SITC 2026
VEGF × PD-(L)1 Bispecifics
A dedicated debate will examine whether this emerging class can establish itself as a new checkpoint combination backbone.
In Vivo Cell Engineering
Targeted LNPs, RNA gene writers and precision delivery platforms could challenge traditional cell therapy manufacturing models.
Cancer Vaccines
Pancreatic RNA vaccines, KRAS-targeted approaches and immunopeptidome-guided platforms will test advances in antigen selection and clinical translation.
Engineered Cytokines
Masking, anchoring and receptor-biased designs aim to improve tolerability while maintaining anti-tumour activity.
SITC 2026: Competitor and Industry Signals
BioNTech SE / Bristol Myers Squibb
Pumitamig will feature in an exploratory Phase 2 ctDNA analysis in extensive-stage small cell lung cancer.
Immatics
Initial IMA402 clinical results and MAGEA4/8 TCER updates could inform the competitive positioning of T-cell engagers.
Syenex / ScaleReady
VivoCell in vivo T-cell engineering and SMART G-Rex manufacturing automation highlight competing approaches to scalability and control.
Artificial Intelligence and Machine Learning at SITC 2026
AI-Driven Therapeutic Design
De novo cytokines, structure-informed TCR discovery and LLM-based antigen prediction signal expanding applications in immunotherapy development.
Response Prediction
Foundation models, radiomics and computational spatial biology will face growing expectations for validation and generalisability.
What We Are Watching After SITC 2026
- Whether VEGF × PD-(L)1 bispecifics demonstrate evidence supporting a new combination backbone.
- Whether in vivo cell engineering delivers sufficient potency and control to compete with manufactured therapies.
- Whether AI-enabled prediction and spatial profiling progress toward prospective patient selection.
Download the SITC 2026 Preview Report
Download the SITC 2026 Preview Report by LucidQuest for a closer look at emerging immuno-oncology developments and the key themes to watch.
📅 Build your schedule around the sessions that matter most.
📥 Download the SITC_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
